TheTechno Optimist.

Laromestrocel (Lomecel-B)Longeveron—Longeveron presents Phase 2a Alzheimer's data showing reduced neuroinflammation at AAIC 2026Laromestrocel (Lomecel-B)Longeveron—Longeveron ELPIS II trial misses primary efficacy endpoint in HLHS but shows favorable safetyLaromestrocel (Lomecel-B)Longeveron—Longeveron named XPRIZE Healthspan Milestone 2 awardee with $1 million award

Longeveron

Laromestrocel allogeneic MSC therapy, aging frailty, Alzheimer's

USpublicest. 2014longeveron.com (opens longeveron.com)Checked 10 Oct

The brief

Analyst view
  • Cell therapy in Phase 2 trials for HLHS, cardiomyopathy, Alzheimer's, and frailty.
  • XPRIZE Healthspan Milestone 2 awardee ($1M in Aug 2026); competing for up to $81M.
  • 644 patients treated; analyzing ELPIS II endpoints and path forward post-primary miss.

Technical approach

As reported
Cell source

Young donor bone marrow

Laromestrocel is derived from mesenchymal stem cells isolated from the bone marrow of young, healthy adult donors, chosen for their regenerative potential.

Mechanism

Multi-pathway action

The therapy works through pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair mechanisms that address aging-related decline.

Indication strategy

Rare and aging diseases

Pipeline targets orphan pediatric conditions (HLHS, PDCM) and aging diseases (Alzheimer's, frailty).

Primer